NCT00257114已完成4 期
Evaluation of VELCADE (Botezomib) for Injection Employed as Re-Treatment for Efficacy, Safety, and Tolerability
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
Multiple myeloma represents the second most common hematological malignancy.VELCADE is a small molecule to treat human malignancies. Its anti-neoplastic effect invovles several distinct mechanisms including inhibition of cell growth. Patients who have relapsed or are refractory to therapy, the standard of care is now VELCADE based on the results of previous clinical trials.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntary written informed consent with the understanding that the consent may be w/d by the patient at any time w/o prejudice to future medical care.
- •Patient previously diagnosed with Multiple Myeloma (MM).
- •Patient previously tolerated 0.7, 1.0, or 1.3 mg/m2/dose of VELCADE alone or therapy combination and had at least a greater/equal 50% reduction in M-Protein upon completion of VELCADE therapy. The DOR prior to VELCADE greater/equal 4 months for the patient population.
- •It has been greater/equal 2 months since the patient's last VELCADE dose and the patient meets certain Lab criteria as per protocol.
- •Patient has a Karnosfsky performance status greater/equal 60%.
- •Patient has a life-expectancy greater than 3 months.
- •Patient has laboratory values (defined in protocol) within 14 days before enrollment.
排除标准
- •Patients with a Hx of PD, minimal response, or stable disease (SD)on first exposure to VELCADE.
- •Patient has received chemotherapy, radiotherapy, immunotherapy or experimental therapy to treat multiple myeloma since their last dose of VELCADE.
- •Patients who achieved a CR or PR but relapsed while on therapy.
- •Patient had major surgery w/in 2 wks before enrollment.
- •Patient has a Hx of allergic reaction to compounds containing boron or mannitol.
- •Patient has peripheral sensory neuropathy of Grade 2 w/pain or greater intensity.
- •Patient has cardiac amyloidosis.
- •Patient has poorly controlled hypertension, diabetes mellitus, or other serious medical or pysychiatric illness.
- •Patient is known to be human immunodeficiency virus (HIV)+.
- •Patient is known to be hepatitis B surface antigen-positive or has known active hepatitis C infection.
- •Patient has an active systemic infection requiring treatment.
- •Female patient is pregnant or breast-feeding. Confirmation must be established by a negative serum B-hCG.
- •Patient is currently enrolled in another clinical research study.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Bortezomib (Velcade) in Patients With Untreated Multiple MyelomaMultiple MyelomaNCT00153920Dana-Farber Cancer Institute66
已完成
1 期
Dose Escalation of Velcade Daily Dose in Patients With Solid TumorsAdvanced or Metastatic Solid TumorsNCT02220049Gustave Roussy, Cancer Campus, Grand Paris18
终止
3 期
MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous TransplantationMultiple MyelomaNCT00256776European Society for Blood and Marrow Transplantation269
撤回
4 期
Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma PatientsNewly Diagnosed Multiple MyelomaNCT04348006Al-Rasheed University College
撤回
1 期
Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple MyelomaRelapsed and Refractory Multiple MyelomaNCT06050512Kathleen Dorritie34